Logo image of IVA.PA

INVENTIVA SA (IVA.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:IVA - FR0013233012 - Common Stock

3.65 EUR
-0.03 (-0.82%)
Last: 12/19/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, IVA scores 2 out of 10 in our fundamental rating. IVA was compared to 82 industry peers in the Biotechnology industry. IVA may be in some trouble as it scores bad on both profitability and health. IVA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IVA has reported negative net income.
In the past year IVA has reported a negative cash flow from operations.
IVA had negative earnings in each of the past 5 years.
In the past 5 years IVA always reported negative operating cash flow.
IVA.PA Yearly Net Income VS EBIT VS OCF VS FCFIVA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

IVA's Return On Assets of -173.74% is on the low side compared to the rest of the industry. IVA is outperformed by 89.16% of its industry peers.
Industry RankSector Rank
ROA -173.74%
ROE N/A
ROIC N/A
ROA(3y)-119.52%
ROA(5y)-84.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IVA.PA Yearly ROA, ROE, ROICIVA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IVA.PA Yearly Profit, Operating, Gross MarginsIVA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

IVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IVA has been increased compared to 1 year ago.
Compared to 5 years ago, IVA has more shares outstanding
IVA has a better debt/assets ratio than last year.
IVA.PA Yearly Shares OutstandingIVA.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IVA.PA Yearly Total Debt VS Total AssetsIVA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

IVA has an Altman-Z score of -1.76. This is a bad value and indicates that IVA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.76, IVA is not doing good in the industry: 63.86% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.76
ROIC/WACCN/A
WACC7.81%
IVA.PA Yearly LT Debt VS Equity VS FCFIVA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

IVA has a Current Ratio of 2.98. This indicates that IVA is financially healthy and has no problem in meeting its short term obligations.
IVA has a better Current ratio (2.98) than 60.24% of its industry peers.
A Quick Ratio of 2.98 indicates that IVA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.98, IVA is in the better half of the industry, outperforming 65.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.98
Quick Ratio 2.98
IVA.PA Yearly Current Assets VS Current LiabilitesIVA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

IVA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.31%.
The Revenue for IVA has decreased by -12.84% in the past year. This is quite bad
IVA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.62% yearly.
EPS 1Y (TTM)-74.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.76%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%

3.2 Future

Based on estimates for the next years, IVA will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.26% on average per year.
IVA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 123.56% yearly.
EPS Next Y43.78%
EPS Next 2Y24.76%
EPS Next 3Y14.52%
EPS Next 5Y16.26%
Revenue Next Year-15.08%
Revenue Next 2Y-39.27%
Revenue Next 3Y62.43%
Revenue Next 5Y123.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IVA.PA Yearly Revenue VS EstimatesIVA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
IVA.PA Yearly EPS VS EstimatesIVA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IVA.PA Price Earnings VS Forward Price EarningsIVA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVA.PA Per share dataIVA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as IVA's earnings are expected to grow with 14.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.76%
EPS Next 3Y14.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INVENTIVA SA

EPA:IVA (12/19/2025, 7:00:00 PM)

3.65

-0.03 (-0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21 2025-11-21
Earnings (Next)02-16 2026-02-16/amc
Inst Owners43.01%
Inst Owner ChangeN/A
Ins Owners4.97%
Ins Owner ChangeN/A
Market Cap697.22M
Revenue(TTM)13.61M
Net Income(TTM)-311.00M
Analysts87.14
Price Target12.18 (233.7%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.6%
PT rev (3m)13.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)7.95%
EPS NY rev (3m)-56.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-73.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 51.22
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.62
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.07
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -173.74%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-119.52%
ROA(5y)-84.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.75%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.98
Quick Ratio 2.98
Altman-Z -1.76
F-Score4
WACC7.81%
ROIC/WACCN/A
Cap/Depr(3y)20.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.76%
Cap/Sales(5y)20.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.76%
EPS Next Y43.78%
EPS Next 2Y24.76%
EPS Next 3Y14.52%
EPS Next 5Y16.26%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%
Revenue Next Year-15.08%
Revenue Next 2Y-39.27%
Revenue Next 3Y62.43%
Revenue Next 5Y123.56%
EBIT growth 1Y2.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.14%
EBIT Next 3Y3.93%
EBIT Next 5Y21.53%
FCF growth 1Y-42.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.88%
OCF growth 3YN/A
OCF growth 5YN/A

INVENTIVA SA / IVA.PA FAQ

What is the ChartMill fundamental rating of INVENTIVA SA (IVA.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IVA.PA.


What is the valuation status of INVENTIVA SA (IVA.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to INVENTIVA SA (IVA.PA). This can be considered as Overvalued.


Can you provide the profitability details for INVENTIVA SA?

INVENTIVA SA (IVA.PA) has a profitability rating of 0 / 10.


How financially healthy is INVENTIVA SA?

The financial health rating of INVENTIVA SA (IVA.PA) is 3 / 10.